Skip to content

RACCOON

Endobiliary radiofrequency ablation for malignant biliary obstruction due to perihilar cholangiocarcinoma: a randomized controlled trial - RACCOON

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52313
Enrollment
70
Registered
2022-03-24
Start date
2022-10-25
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bile duct cancer, Cholangiocarcinoma Bile duct cancer

Interventions

eRFA prior to placement of an uncovered self-expanding metal stent (or plastic stent in case not feasible) compared with stent placement only.

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older. - Capable of providing written and oral informed consent. - Histological or cytological proof of perihilar cholangiocarcinoma (adenocarcinoma). - Perihilar biliary obstruction with indication for drainage with uSEMS.* - Advanced (no candidate for surgical resection) due to metastases, vascular or lymph node (N2). involvement on imaging or during staging laparoscopy according to multidisciplinary team (MDT). *Only patients with pCCA are eligible however in case of reasonable doubt between intrahepatic CCA with a perihilar biliary obstruction or massforming pCCA, patients can be included.

Exclusion criteria

Exclusion criteria: - Patients who potentially qualify for curative resection of pCCA. - pCCA eligible for liver transplantation. - Life-expectancy less than 3 months. - ERCP and PTC technically not feasible. - Uncontrolled coagulopathy (PTT >1,5x prolonged or thrombocytes below 40*10E9/L). - Ongoing cholangitis or liver abscess. Patients are required to be off antibiotic treatment for cholangitis and/or liver abscess at least 7 days. - Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study. - Patients who are pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the time to biliary obstruction.

Secondary

MeasureTime frame
Secondary endpoints include technical and functional success, the effect on quality of life, overall survival, adverse events, number of re-interventions, time to re-interventions, need for external drains, and evaluation of the effect of repeated eRFA on stent patency.

Countries

Belgium, Czech Republic, Netherlands, Romania, United States

Contacts

Public ContactR.P. Voermans

Amsterdam UMC

r.p.voermans@amsterdamumc.nl+31204440613

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026